Amneal Pharmaceuticals, Inc. (FRA:2DT)

Amneal Pharmaceuticals Statistics

Total Valuation

FRA:2DT has a market cap or net worth of EUR 3.33 billion. The enterprise value is 5.52 billion.

Market Cap	3.33B
Enterprise Value	5.52B

Important Dates

The next estimated earnings date is Friday, March 6, 2026.

Earnings Date	Mar 6, 2026
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	314.36M
Shares Outstanding	n/a
Shares Change (YoY)	+9.44%
Shares Change (QoQ)	+0.74%
Owned by Insiders (%)	39.17%
Owned by Institutions (%)	48.37%
Float	191.24M

Valuation Ratios

The trailing PE ratio is 661.98 and the forward PE ratio is 14.16.

PE Ratio	661.98
Forward PE	14.16
PS Ratio	1.33
PB Ratio	-92.61
P/TBV Ratio	n/a
P/FCF Ratio	15.65
P/OCF Ratio	11.92
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 9.96, with an EV/FCF ratio of 25.96.

EV / Earnings	1,098.11
EV / Sales	2.19
EV / EBITDA	9.96
EV / EBIT	16.75
EV / FCF	25.96

Financial Position

The company has a current ratio of 2.13

Current Ratio	2.13
Quick Ratio	1.31
Debt / Equity	n/a
Debt / EBITDA	4.17
Debt / FCF	10.76
Interest Coverage	1.56

Financial Efficiency

Return on Equity (ROE)	n/a
Return on Assets (ROA)	6.79%
Return on Invested Capital (ROIC)	9.12%
Return on Capital Employed (ROCE)	14.00%
Revenue Per Employee	301,381
Profits Per Employee	606
Employee Count	8,300
Asset Turnover	0.83
Inventory Turnover	3.04

Taxes

In the past 12 months, FRA:2DT has paid 9.41 million in taxes.

Income Tax	9.41M
Effective Tax Rate	16.08%

Stock Price Statistics

The stock price has increased by +43.24% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+43.24%
50-Day Moving Average	9.07
200-Day Moving Average	7.56
Relative Strength Index (RSI)	66.48
Average Volume (20 Days)	8

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	3.86

Income Statement

In the last 12 months, FRA:2DT had revenue of EUR 2.50 billion and earned 5.03 million in profits. Earnings per share was 0.01.

Revenue	2.50B
Gross Profit	932.16M
Operating Income	326.72M
Pretax Income	58.51M
Net Income	5.03M
EBITDA	531.67M
EBIT	326.72M
Earnings Per Share (EPS)	0.01

Balance Sheet

The company has 173.42 million in cash and 2.29 billion in debt, giving a net cash position of -2.12 billion.

Cash & Cash Equivalents	173.42M
Total Debt	2.29B
Net Cash	-2.12B
Net Cash Per Share	n/a
Equity (Book Value)	-35.95M
Book Value Per Share	-0.30
Working Capital	832.16M

Cash Flow

In the last 12 months, operating cash flow was 279.35 million and capital expenditures -66.60 million, giving a free cash flow of 212.75 million.

Operating Cash Flow	279.35M
Capital Expenditures	-66.60M
Free Cash Flow	212.75M
FCF Per Share	n/a

Margins

Gross margin is 37.26%, with operating and profit margins of 13.06% and 0.20%.

Gross Margin	37.26%
Operating Margin	13.06%
Pretax Margin	2.34%
Profit Margin	0.20%
EBITDA Margin	21.25%
EBIT Margin	13.06%
FCF Margin	8.50%

Dividends & Yields

FRA:2DT does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-9.44%
Shareholder Yield	-9.44%
Earnings Yield	0.15%
FCF Yield	6.39%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value
Lynch Upside
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

FRA:2DT has an Altman Z-Score of 1.7 and a Piotroski F-Score of 7. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	1.7
Piotroski F-Score	7